XML 63 R25.htm IDEA: XBRL DOCUMENT v3.19.3
Quarterly Financial Data (Unaudited)
 12 Months Ended
Sep. 27, 2019
Quarterly Financial Information Disclosure [Abstract]  
Quarterly Financial Data QUARTERLY FINANCIAL DATA (UNAUDITED) 
 
 
Fiscal Year 2019
(In millions, except per share amounts)
 
First
Quarter (1)
 
Second
Quarter
 
Third
Quarter (2)
 
Fourth
Quarter (3)
 
Total
Year
Total revenues
 
$
741.0

 
$
779.4

 
$
825.8

 
$
878.9

 
$
3,225.1

Gross margin
 
$
316.1

 
$
318.2

 
$
351.4

 
$
384.6

 
$
1,370.3

Net earnings
 
$
103.9

 
$
88.4

 
$
29.5

 
$
70.4

 
$
292.2

Net earnings attributable to Varian
 
$
103.2

 
$
88.6

 
$
29.4

 
$
70.7

 
$
291.9

 
 
 
 
 
 
 
 
 
 
 
Net earnings per share - basic
 
$
1.13

 
$
0.97

 
$
0.32

 
$
0.78

 
$
3.21

Net earnings per share - diluted
 
$
1.12

 
$
0.96

 
$
0.32

 
$
0.77

 
$
3.18

 
 
 
 
 
 
 
 
 
 
 
 
 
Fiscal Year 2018
(In millions, except per share amounts)
 
First
Quarter (4)
 
Second
Quarter (5)
 
Third
Quarter (6)
 
Fourth
Quarter (7)
 
Total
Year
Total revenues
 
$
678.5

 
$
729.9

 
$
709.1

 
$
801.6

 
$
2,919.1

Gross margin
 
$
302.8

 
$
318.5

 
$
313.6

 
$
338.7

 
$
1,273.6

Net earnings (loss)
 
$
(112.2
)
 
$
73.2

 
$
72.5

 
$
116.8

 
$
150.3

Net earnings attributable to Varian
 
$
(112.3
)
 
$
73.2

 
$
72.6

 
$
116.4

 
$
149.9

 
 
 
 
 
 
 
 
 
 
 
Net earnings (loss) per share - basic
 
$
(1.22
)
 
$
0.80

 
$
0.79

 
$
1.27

 
$
1.64

Net earnings (loss) per share - diluted
 
$
(1.22
)
 
$
0.79

 
$
0.79

 
$
1.26

 
$
1.62



(1) 
In the first quarter of fiscal year 2019, net earnings includes a $22.0 million gain on the sale of our investment in Augmenix.
(2) 
In the third quarter of fiscal year 2019, net earnings includes a $50.5 million goodwill impairment charge related to the Company's Proton Solutions business and a $20.8 million charge associated with the write-off of in-process R&D related to an acquisition.
(3) 
In the fourth quarter of fiscal year 2019, net earnings includes an $18.6 million charge to acquisition-related expenses due to an increase to the fair value of contingent consideration related to an acquisition.
(4) 
In the first quarter of fiscal year 2018, net earnings includes a $207.1 million income tax expense related to the tax effect of a change in law related to the Act.
(5) 
In the second quarter of fiscal year 2018, net earnings includes a $16.4 million loss related to hedging the anticipated Australian dollar purchase price for Sirtex and an $11.1 million impairment charge related to our MPTC subordinated loan.
(6) 
In the third quarter of fiscal year 2018, net earnings includes a $13.3 million loss related to hedging the anticipated Australian dollar purchase price of the Sirtex acquisition, an $11.0 million impairment charge related to our MPTC subordinated loan, acquisition costs of $8.4 million, partially offset by the net $9.0 million breakup fee received from Sirtex in connection with the termination of the acquisition.
(7) 
In the fourth quarter of fiscal year 2018, net earnings includes a $8.0 million benefit to income tax expense due to the partial release of a valuation allowance as the result of an acquisition and a $7.1 million benefit to income tax expense related to the Act.